Can T-cell and B-cell excision circles predict development of inhibitors in pediatric hemophilia A?
Journal
Pediatric research
ISSN: 1530-0447
Titre abrégé: Pediatr Res
Pays: United States
ID NLM: 0100714
Informations de publication
Date de publication:
05 2023
05 2023
Historique:
received:
04
04
2022
accepted:
05
08
2022
revised:
06
07
2022
medline:
12
5
2023
pubmed:
1
9
2022
entrez:
31
8
2022
Statut:
ppublish
Résumé
Hemophilia A (HA) therapy requires intravenous replacement infusions of factor (F) VIII concentrate. Inhibitors are high-affinity immunoglobulin G that are directed against FVIII and thereby render replacement therapy ineffective. This complication has significant prognostic implications. We aimed to examine the immune system involvement in inhibitor formation specifically T-cell excision circles (TRECs) and B-cell excision circles (KRECs), markers of new T and B cells, respectively, and examine them as surrogate markers for inhibitor formation. Blood samples were collected from 35 children with severe HA. Children were divided into two groups: with FVIII inhibitors and without FVIII inhibitors. TRECs and KRECs were measured in peripheral blood. A total of 11 patients with inhibitors and 24 without were evaluated. Children with inhibitors had higher levels of TRECs however not statistically significant (p = 0.085). CjKREC levels were higher in the inhibitor patients (p = 0.003). Moreover, the sj/cjKREC ratio was lower in the inhibitor patients (p = 0.015). Our findings may add to the notion that inhibitor formation is attributed to humoral immunity due to peripheral B-cell expansion and loss of peripheral tolerance. Improved knowledge regarding the involvement of the immune system in the formation of FVIII inhibitors will enable better therapy tailoring in the era of non-replacement therapies. The etiology of FVIII inhibitor formation is multifactorial, in which the immune system plays a pivotal role. Our findings may add to the notion that inhibitor formation is attributed to humoral immunity due to peripheral B-cell expansion and production of antibodies against FVIII. Improved knowledge regarding the involvement of the immune system in the development of FVIII inhibitors will enable the identification of patients prone to inhibitor development and better therapy tailoring in the new era of non-replacement therapies.
Sections du résumé
BACKGROUND
Hemophilia A (HA) therapy requires intravenous replacement infusions of factor (F) VIII concentrate. Inhibitors are high-affinity immunoglobulin G that are directed against FVIII and thereby render replacement therapy ineffective. This complication has significant prognostic implications. We aimed to examine the immune system involvement in inhibitor formation specifically T-cell excision circles (TRECs) and B-cell excision circles (KRECs), markers of new T and B cells, respectively, and examine them as surrogate markers for inhibitor formation.
METHODS
Blood samples were collected from 35 children with severe HA. Children were divided into two groups: with FVIII inhibitors and without FVIII inhibitors. TRECs and KRECs were measured in peripheral blood.
RESULTS
A total of 11 patients with inhibitors and 24 without were evaluated. Children with inhibitors had higher levels of TRECs however not statistically significant (p = 0.085). CjKREC levels were higher in the inhibitor patients (p = 0.003). Moreover, the sj/cjKREC ratio was lower in the inhibitor patients (p = 0.015).
CONCLUSIONS
Our findings may add to the notion that inhibitor formation is attributed to humoral immunity due to peripheral B-cell expansion and loss of peripheral tolerance. Improved knowledge regarding the involvement of the immune system in the formation of FVIII inhibitors will enable better therapy tailoring in the era of non-replacement therapies.
IMPACT
The etiology of FVIII inhibitor formation is multifactorial, in which the immune system plays a pivotal role. Our findings may add to the notion that inhibitor formation is attributed to humoral immunity due to peripheral B-cell expansion and production of antibodies against FVIII. Improved knowledge regarding the involvement of the immune system in the development of FVIII inhibitors will enable the identification of patients prone to inhibitor development and better therapy tailoring in the new era of non-replacement therapies.
Identifiants
pubmed: 36045224
doi: 10.1038/s41390-022-02268-5
pii: 10.1038/s41390-022-02268-5
doi:
Substances chimiques
Factor VIII
9001-27-8
Coagulants
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1546-1550Informations de copyright
© 2022. The Author(s), under exclusive licence to the International Pediatric Research Foundation, Inc.
Références
Blanchette, V. S. et al. Definitions in hemophilia: communication from the SSC of the ISTH. J. Thromb. Haemost. 12, 1935–1939 (2014).
doi: 10.1111/jth.12672
pubmed: 25059285
Oldenburg, J. & Pavlova, A. Genetic risk factors for inhibitors to factors VIII and IX. Haemophilia 6(12 Sup), 15–22 (2006).
doi: 10.1111/j.1365-2516.2006.01361.x
Hazenberg, M. D. et al. Increased cell division but not thymic dysfunction rapidly affects the T-cell receptor excision circle content of the naive T cell population in HIV-1 infection. Nat. Med. 6, 1036–1042 (2000).
doi: 10.1038/79549
pubmed: 10973325
Serana, F. et al. Thymic and bone marrow output in patients with common variable immunodeficiency. J. Clin. Immunol. 31, 540–549 (2011).
doi: 10.1007/s10875-011-9526-6
pubmed: 21491094
Levy-Mendelovich, S. et al. Quantification of specific T and B cells immunological markers in children with chronic and transient ITP. Pediatr. Blood Cancer 64, 12 (2017).
doi: 10.1002/pbc.26646
Machnes-Maayan, D. et al. Insight into normal thymic activity by assessment of peripheral blood samples. Immunol. Res. 61, 198–205 (2014).
doi: 10.1007/s12026-014-8558-4
Lev, A. et al. The kinetics of early T and B cell immune recovery after bone marrow transplantation in RAG-2-deficient SCID patients. PLoS One 7, e30494 (2012).
doi: 10.1371/journal.pone.0030494
pubmed: 22295088
pmcid: 3266259
Somech, R. T-cell receptor excision circles in primary immunodeficiencies and other T-cell disorders. Curr. Opin. Allergy Clin. Immunol. 11, 517–524 (2011).
doi: 10.1097/ACI.0b013e32834c233a
pubmed: 21971333
Hampe, C. S. B cells in autoimmune diseases. Scientifica 2012, 215308 (2012).
doi: 10.6064/2012/215308
pubmed: 23807906
pmcid: 3692299
Amariglio, N. et al. T-cell compartment in synovial fluid of pediatric patients with JIA correlates with disease phenotype. J. Clin. Immunol. 31, 1021–1028 (2011).
doi: 10.1007/s10875-011-9580-0
pubmed: 21901393
Yurasov, S. et al. Defective B cell tolerance checkpoints in systemic lupus erythematosus. J. Exp. Med. 201, 703–711 (2005).
doi: 10.1084/jem.20042251
pubmed: 15738055
pmcid: 2212839
Samuels, J., Ng, Y. S., Coupillaud, C., Paget, D. & Meffre, E. Impaired early B cell tolerance in patients with rheumatoid arthritis. J. Exp. Med. 201, 1659–1667 (2005).
doi: 10.1084/jem.20042321
pubmed: 15897279
pmcid: 2212916
Lev, A. et al. Characterizing T cells in SCID patients presenting with reactive or residual T lymphocytes. Clin. Dev. Immunol. 2012, 261470 (2012).
doi: 10.1155/2012/261470
pubmed: 23243423
pmcid: 3513974
Astermark, J. Why do inhibitors develop? Principles of and factors influencing the risk for inhibitor development in haemophilia. Haemophilia 3(12 Suppl), 52–60 (2006).
doi: 10.1111/j.1365-2516.2006.01261.x
Ljung, R., Petrini, P., Lindgren, A. C., Tengborn, L. & Nilsson, I. M. Factor VIII and factor IX inhibitors in haemophiliacs. Lancet 339, 1550 (1992).
doi: 10.1016/0140-6736(92)91324-2
pubmed: 1351234
Luna-Záizar, H. et al. F8 inversions of introns 22 and 1 confer a moderate risk of inhibitors in Mexican patients with severe hemophilia A. Concordance analysis and literature review. Blood Cells Mol. Dis. 71, 45–52 (2018).
doi: 10.1016/j.bcmd.2018.02.003
pubmed: 29544691
Ghosh, K. & Shetty, S. Immune response to FVIII in hemophilia A: an overview of risk factors. Clin. Rev. Allergy Immunol. 37, 58–66 (2009).
doi: 10.1007/s12016-009-8118-1
pubmed: 19148784
Doshi, B. S. et al. B cell-activating factor modulates the factor VIII immune response in hemophilia A. J. Clin. Invest. 131, e142906 (2021).
doi: 10.1172/JCI142906
pubmed: 33651716
pmcid: 8262462
Peyvandi, F. et al. RandomizeD TRIAL OF FActor VIII and neutralizing antibodies in hemophilia A. N. Engl. J. Med. 374, 2054–2064 (2016).
doi: 10.1056/NEJMoa1516437
pubmed: 27223147
Carcao, M., Re, W. & Ewenstein, B. The role of previously untreated patient studies in understanding the development of FVIII inhibitors. Haemophilia 22, 22–31 (2016).
doi: 10.1111/hae.12790
pubmed: 26315604
White, G. C. II, Kempton, C. L., Grimsley, A., Nielsen, B. & Roberts, H. R. Cellular immune responses in hemophilia: why do inhibitors develop in some, but not all hemophiliacs? J. Thromb. Haemost. 3, 1676–1681 (2005).
doi: 10.1111/j.1538-7836.2005.01375.x
pubmed: 16102033
Rammensee, H. G., Friede, T. & Stevanoviic, S. MHC ligands and peptide motifs: first listing. Immunogenetics 41, 178–228 (1995).
doi: 10.1007/BF00172063
pubmed: 7890324
Schwaab, R. et al. Haemophilia A: mutation type determines risk of inhibitor formation. Thromb. Haemost. 74, 1402–1406 (1995).
doi: 10.1055/s-0038-1649954
pubmed: 8772209
Hay, C. R. et al. HLA class II profile: a weak determinant of factor VIII inhibitor development in severe hemophilia A. A UKHCDO Inhibitor Working Party. Thromb. Haemost. 77, 234–237 (1997).
doi: 10.1055/s-0038-1655944
pubmed: 9157572
Abdulqader, A. M. R., Mohammed, A. I. & Rachid, S. Polymorphisms in the cytotoxic T lymphocyte-associated protein-4 immune regulatory gene and their impact on inhibitor development in patients with hemophilia A. J. Int. Med. Res. 47, 4981–4992 (2019).
doi: 10.1177/0300060519860329
pubmed: 31524022
pmcid: 6833422
Chaves, D., Belisário, A., Castro, G., Santoro, M. & Rodrigues, C. Analysis of cytokine genes polymorphism as markers for inhibitor development in haemophilia A. Int J. Immunogenet 37, 79–82 (2010).
doi: 10.1111/j.1744-313X.2009.00893.x
pubmed: 20082647
Hoyer, L. W. The incidence of factor VIII inhibitors in patients with severe hemophilia A. Adv. Exp. Med. Biol. 386, 35–45 (1995).
doi: 10.1007/978-1-4613-0331-2_3
pubmed: 8851013
Pratt, K. P. & Thompson, A. R. B-cell and T-cell epitopes in anti-factor VIII immune responses. Rev. Bras. Hematol. Hemoter. 37, 80–95 (2009).
de Alencar, J. B. et al. Importance of immune response genes in hemophilia A. Rev. Bras. Hematol. Hemoter. 35, 280–286 (2013).
doi: 10.5581/1516-8484.20130095
pubmed: 24106448
pmcid: 3789435
Thewissen, M. et al. Analyses of immunosenescent markers in patients with autoimmune disease. Clin. Immunol. 123, 209–218 (2007).
doi: 10.1016/j.clim.2007.01.005
pubmed: 17317320